Credit Suisse’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $7.53M | Buy |
88,271
+1,275
| +1% | +$100K | 0.01% | 1064 |
|
|
2023
Q4 | $7.44M | Buy |
86,996
+6,551
| +8% | +$566K | 0.01% | 1101 |
|
|
2023
Q3 | $7.21M | Sell |
80,445
-78
| -0.1% | -$6.96K | 0.01% | 1055 |
|
|
2023
Q2 | $6.86M | Buy |
80,523
+8,583
| +12% | +$726K | 0.01% | 1137 |
|
|
2023
Q1 | $5.95M | Buy |
71,940
+2,971
| +4% | +$241K | 0.01% | 1198 |
|
|
2022
Q4 | $5.42M | Buy |
68,969
+13,952
| +25% | +$1.12M | 0.01% | 1252 |
|
|
2022
Q3 | $4.07M | Buy |
55,017
+4,889
| +10% | +$351K | ﹤0.01% | 1381 |
|
|
2022
Q2 | $3.27M | Sell |
50,128
-2,054
| -4% | -$122K | ﹤0.01% | 1578 |
|
|
2022
Q1 | $3.3M | Buy |
52,182
+3,322
| +7% | +$181K | ﹤0.01% | 1739 |
|
|
2021
Q4 | $2.59M | Sell |
48,860
-11,526
| -19% | -$702K | ﹤0.01% | 2589 |
|
|
2021
Q3 | $4.26M | Sell |
60,386
-16,552
| -22% | -$1.04M | ﹤0.01% | 2198 |
|
|
2021
Q2 | $5.13M | Buy |
76,938
+17,304
| +29% | +$1.22M | ﹤0.01% | 2061 |
|
|
2021
Q1 | $6.62M | Sell |
59,634
-142,118
| -70% | -$17.6M | ﹤0.01% | 1844 |
|
|
2020
Q4 | $24M | Buy |
201,752
+54,389
| +37% | +$5.86M | 0.01% | 1072 |
|
|
2020
Q3 | $12.9M | Buy |
147,363
+62,849
| +74% | +$5.49M | 0.01% | 1237 |
|
|
2020
Q2 | $7.57M | Sell |
84,514
-239,386
| -74% | -$24.2M | 0.01% | 1449 |
|
|
2020
Q1 | $32.3M | Buy |
323,900
+167,626
| +107% | +$18.2M | 0.03% | 604 |
|
|
2019
Q4 | $18M | Buy |
156,274
+100,695
| +181% | +$12.2M | 0.01% | 1090 |
|
|
2019
Q3 | $7.01M | Sell |
55,579
-8,925
| -14% | -$1.13M | 0.01% | 1529 |
|
|
2019
Q2 | $7.76M | Sell |
64,504
-32,823
| -34% | -$3.23M | 0.01% | 1468 |
|
|
2019
Q1 | $8.52M | Buy |
97,327
+11,998
| +14% | +$1.09M | 0.01% | 1334 |
|
|
2018
Q4 | $8.54M | Sell |
85,329
-34,041
| -29% | -$3.58M | 0.01% | 1244 |
|
|
2018
Q3 | $13.7M | Sell |
119,370
-6,056
| -5% | -$627K | 0.01% | 1076 |
|
|
2018
Q2 | $11.2M | Buy |
125,426
+27,151
| +28% | +$2.29M | 0.01% | 1165 |
|
|
2018
Q1 | $7.19M | Buy |
98,275
+8,761
| +10% | +$601K | 0.01% | 1465 |
|
|
2017
Q4 | $5.2M | Sell |
89,514
-20,205
| -18% | -$1.06M | ﹤0.01% | 1755 |
|
|
2017
Q3 | $4.92M | Buy |
109,719
+34,308
| +45% | +$1.43M | ﹤0.01% | 1774 |
|
|
2017
Q2 | $2.98M | Buy |
75,411
+943
| +1% | +$38.7K | ﹤0.01% | 1963 |
|
|
2017
Q1 | $3.02M | Sell |
74,468
-6,939
| -9% | -$271K | ﹤0.01% | 2031 |
|
|
2016
Q4 | $3.27M | Buy |
81,407
+21,922
| +37% | +$827K | ﹤0.01% | 2016 |
|
|
2016
Q3 | $2.15M | Buy |
59,485
+6,161
| +12% | +$211K | ﹤0.01% | 2322 |
|
|
2016
Q2 | $1.54M | Buy |
53,324
+18,740
| +54% | +$566K | ﹤0.01% | 2544 |
|
|
2016
Q1 | $1.21M | Sell |
34,584
-14,946
| -30% | -$483K | ﹤0.01% | 2580 |
|
|
2015
Q4 | $1.6M | Buy |
49,530
+1,038
| +2% | +$33.7K | ﹤0.01% | 2440 |
|
|
2015
Q3 | $1.57M | Sell |
48,492
-1,564
| -3% | -$58.9K | ﹤0.01% | 2443 |
|
|
2015
Q2 | $2.07M | Buy |
50,056
+13,473
| +37% | +$568K | ﹤0.01% | 2526 |
|
|
2015
Q1 | $1.64M | Buy |
36,583
+925
| +3% | +$38.7K | ﹤0.01% | 2554 |
|
|
2014
Q4 | $1.33M | Sell |
35,658
-14,426
| -29% | -$528K | ﹤0.01% | 2892 |
|
|
2014
Q3 | $1.75M | Buy |
50,084
+17,474
| +54% | +$624K | ﹤0.01% | 2600 |
|
|
2014
Q2 | $1.15M | Sell |
32,610
-125,335
| -79% | -$4.19M | ﹤0.01% | 3160 |
|
|
2014
Q1 | $5.15M | Buy |
157,945
+114,450
| +263% | +$4.37M | 0.01% | 1736 |
|
|
2013
Q4 | $1.83M | Sell |
43,495
-70,772
| -62% | -$2.91M | ﹤0.01% | 2742 |
|
|
2013
Q3 | $4.56M | Buy |
114,267
+17,853
| +19% | +$749K | ﹤0.01% | 1721 |
|
|
2013
Q2 | $3.99M | Buy |
+96,414
| New | +$3.9M | ﹤0.01% | 1766 |
|
Other funds holding HAE
RA
Credit Suisse's HAE Position: Q1 2024 in Review
Credit Suisse increased its Haemonetics (HAE) stake by 1.5% in Q1 2024, buying an estimated $100K and bringing the position to 88,271 shares worth $7.53M. The position accounts for 0.01% of the portfolio, ranked #1064.
Credit Suisse first reported a position in HAE in Q2 2013 and has held it in 44 quarters since. The position peaked at $32.3M in Q1 2020. 298 funds tracked by Wall St. Rank hold HAE as of Q1 2024.
- Credit Suisse held 88,271 shares of Haemonetics worth $7.53M as of Q1 2024.
- Credit Suisse bought 1,275 Haemonetics shares in Q1 2024, an estimated $100K.
- Haemonetics made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #1064 holding.
- Credit Suisse first reported a position in Haemonetics in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Haemonetics position peaked at $32.3M in Q1 2020.
- 298 funds tracked by Wall St. Rank held Haemonetics as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.